Skip to content
ES
MARKETS / NASDAQ / SLN
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Silence Therapeutics PLC SLN

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$559,000
▼ 98.7% YoY
$-88.6M
$-62.3M
In brief

What this company does

Our proprietary mRNAi GOLD™ (GalNAc Oligonucleotide Discovery) platform consists of siRNA product candidates designed to precisely target and ‘silence’ specific disease-associated genes in the liver. Divesiran (SLN124) is our potential first-in-class siRNA in Phase 2 development for polycythemia vera, or PV. SLN548 is our Phase 1 ready siRNA product candidate that works by "silencing" the complement factor B, or CFB, gene, potentially playing a therapeutic role in conditions associated with over activation of this pathway, including complement-mediated renal diseases, among others. Zerlasiran (SLN360) is our Phase 3 ready siRNA product candidate for cardiovascular disease that works by "silencing" the LPA gene, lowering production of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a), that has been associated with an increased risk of cardiovascular events.

Written from the business description in Silence Therapeutics plc's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 559,000.00
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -88.6
20M40M-40M-80M2022202320242025
Compound annual growth
−70.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−15852 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -16292.8% · Net -15851.9%
-5000%-10000%-15000%2022202320242025
ROE
FY2025 · ROE -90.3%
-100%-200%2022202320242025
Gross margin61.5%
Operating margin-16292.8%
Net margin-15851.9%
Return on assets-53.0%
EBITDAUSD -90.8M

Each USD of equity lost 90 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -62.3
-25.0M-50.0M2022202320242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 131.4M
EquityUSD 62.3M
CashUSD 11.3M
Current ratio8.72×

Equity funds 47% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1−0.1
Income tax $B0.00.00.00.0
Net income $B−0.1−0.0−0.1−0.1
Free cash flow $B−0.1−0.1−0.0−0.1
EPS, diluted $−0.63−0.33−0.49−0.52
Dividend / sh $····
Payout %····
ROE %−90.3−58.1−220.4−184.9
Shares out B0.140.140.120.11

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 18 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 77 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsnot stated in the filings
SEC categorysmaller reporting company
Data on record since2022

Share this section

Download image